2. Шелыгин Ю.А., Ивашкин В.Т., Белоусова Е.А.и др. Язвенный колит (К51), взрослые. Колопроктология. 2023;22(1):10–44. Doi: 10.33878/2073-7556-2023-22-1-10-44.

3. Ивашкин В.Т., Шелыгин Ю.А., Абдулганиева Д.И. и др. Клинические рекомендации по диагностике и лечению болезни Крона у взрослых (проект). Колопроктология. 2020;19(2):8–38.

4. Harbord M., Annese V., Vavricka S.R., et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2016;10(3):239–54. Doi: 10.1093/ecco-jcc/jjv213.

5. Brocq L., Simon C. Contribution a l’etude du phagedenisme. Bull Soc Med Hop. Paris. 1908.P. 290–307.

6. Brunsting L.A., Goeckerman W.H., O’Leary P.A. Pyoderma (ecthyma) gangrenosum. Arch Derm Syphilol. 1930;22(4):655–80. Doi: 10.1001/archderm.1930.01440160053009.

7. Langan S.M., Groves R.W., Card T.R., et al. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol. 2012;132:2166–70. Doi: 10.1038/jid.2012.130.

8. Ashchyan H.J., Butler D.C., Nelson C.A., et al. The association of age with clinical presentation and comorbidities of pyoderma gangrenosum. JAMA. Dermatol. 2018;154(4):409–13. Doi: 10.1001/jamadermatol.2017.5978.

9. Yamamoto T. Epidemiology of pyoderma gangrenosum in Japanese patients by questionnaire survey. J Dermatol. 2019;46(4):e145–46. Doi: 10.1111/1346-8138.14658.

10. Monari P., Moro R., Motolese A., et al. Epidemiology of pyoderma gangrenosum: results from an Italian prospective multicentre study. Int Wound J. 2018;15(6):875–79. Doi: 10.1111/iwj.12939.

11. Hobbs M.M., Ortega-Loayza A.G. Pyoderma gangrenosum: from historical perspectives to emerging investigations. Int Wound J. 2020;17(5):1255–65. Doi: 10.1111/iwj.13389.

12. Maronese C.A., Pimentel M.A., Li M.M., et al. Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments. Am J Clin Dermatol. 2022;23(5):615–34. Doi: 10.1007/s40257-022-00699-8.

13. Патрушев А.В., Самцов А.В., Барбинов В.В. и др. Гангренозная пиодермия: трудности в диагностике и терапии. Вестник дерматологии и венерологии. 2014;90(1):25–9.

14. Genovese G., Tavecchio S., Berti E., et al. Pyoderma gangrenosum-like ulcerations in granulomatosis with polyangiitis: two cases and literature review. Rheumatol Int. 2018;38(6):1139–51. Doi: 10.1007/s00296-018-4035-z.

15. Martinelli V.F., Martinelli B.P., Dantas de Oliveira L.S., et al. Atypical forms of pyoderma gangrenosum in inflammatory bowel disease: report of four cases and literature review. Int Med Case Rep J. 2022;15:449–56. Doi: 10.2147/IMCRJ.S376915.

16. Chen B., Li W., Qu B. Practical aspects of the diagnosis and management of pyderma gangrenosum Front Med. 2023;10:1134939. Doi: 10.3389/fmed.2023.1134939.

17. Bhat R.M. Pyoderma gangrenosum: an update. Indian Dermatol Online J. 2012;3(1):7–13. Doi: 10.4103/2229-5178.93482.

18. Maverakis E., Marzano A.V., Le S.T., et al. Pyoderma gangrenosum. Nat Rev Dis Primers. 2020;6(1):81. Doi: 10.1038/s41572-20-0213-x

19. Falloon K., Cohen B., Ananthakrishnan A.N., et al. United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease. Aliment Pharmacol Ther. 2022;55(9):1179–91. Doi: 10.1111/apt.16853.

20. Marzano A.V., Borghi A., Meroni P.L., et al. Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation. Br. J. Dermatol. 2016;175(5):882–91. Doi: 10.1111/bjd.14691.

21. Ruocco E., Sangiuliano S., Gravina A.G., et al. Pyoderma gangrenosum: an updated review. J. Eur. Acad. Dermatol. Venereol. 2009;23:1008. Doi: 10.1111/j.1468-3083.2009.03199.x.

22. Schosler L., Fogh K., Bech R. Pyoderma gangrenosum: a retrospective study of cliical characteristics, comorbidities, response to treatment and mortality related to prednisone dose. Acta. Derm. Venereol. 2021;101(4):adv00431. Doi: 10.2340/00015555-3776.

23. von den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol. 1997;137(6):1000–5.

24. Su W.P., Davis M.D., Weenig R.H., et al. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol. 2004;43(11):790–800. Doi: 10.1111/j.1365-4632.2004.02128.x.

25. Maverakis, E., Ma C., Shinkai, K., et al. Diagnostic criteria of ulcerative pyoderma gangrenosum: a Delphi consensus of international experts. JAMA. Dermatol. 2018;154(4):461–66. Doi: 10.1001/jamadermatol.2017.5980.

26. Hammer P., Latour E., Bohnett M., et al. The utility and challenges of histopathlogic evaluation in the diagnosis of nonmalignant skin ulcers. Wound Repair Regen. 2020;28:219–23. Doi: 10.1111/wrr.12780.

27. Jockenhofer F., Wollina U., Salva K.A., et al. The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum. Br. J. Dermatol. 2019;180(3):615–20. Doi: 10.1111/bjd.16401.

28. Адаскевич В.П. Гангренозная пиодермия: современное состояние проблемы. Consilium Medicum. 2021;23(8):603–8.

29. Chen B., Li W., Qu B. Practical aspects of the diagnosis and management of pyderma gangrenosum Front. Med. 2023;10:1134939. Doi: 10.3389/fmed.2023.1134939.

30. Isene R., Bernklev T., Hoie O., et al. Extraintestinal manifestations in Crohn’s diease and ulcerative colitis: results from a prospective, population-based European inception cohort. Scand. J. Gastroenterol. 2014;50(3):300–5. Doi: 10.3109/00365521.2014.99175.

31. States V., O’Brien S., Rai J.P., et al. Pyoderma gangrenosum in inflammatory bowel disease: a systematic review and meta-analysis. Dig. Dis. Sci. 2020;65(9):2675–85. Doi:10.1007/s10620-019-05999-4.

32. Xu A., Strunk A., Garg A., et al. Prevalence of inflammatory bowel disease in patients with pyoderma gangrenosum: a population-based analysis. J. Am. Acad. Dermatol. 2022;86(6):1351–52. Doi: 10.1016/j.jaad.2021.05.006.

33. Langan S.M., Groves R.W., Card T.R., et al. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J. Invest. Dermatol. 2012;132:2166–70. Doi: 10.1038/jid.2012.130.

34. Ashchyan H.J., Butler D.C., Nelson C.A., et al. The association of age with clinical presentation and comorbidities of pyoderma gangrenosum. JAMA. Dermatol. 2018; 154(4):409–13. Doi: 10.1001/jamadermatol.2017.5978.

35. Yamamoto T., Yamasaki K., Yamanaka K., et al. Clinical guidance of pyoderma gagrenosum 2022. J Dermatol. 2023. Doi: 10.1111/1346-8138.16845 (Online ahead of print).

36. Weizman A.V., Huang B., Targan S., et al. Pyoderma gangrenosum among patients with inflammatory bowel disease: a descriptive cohort study. J Cutan Med Surg. 2014;18(5):361.

37. Strunck J., Cutler B., Latour E., et al. Wound care dressings for pyoderma gangrenosum. J Am Acad Dermatol. 2022;86:458–60. Doi: 10.1016/j.jaad.2021.09.053.

38. Niu R., Zheng J., Ding D., et al. Giant pyoderma gangrenosum in a patient with ulcerative colitis: a case report. Medicine (Baltimore). 2020;99(6):e18795. Doi: 10.1097/MD.0000000000018795.

39. Chaby G., Viseux V., Poulain J.F., et al. Topical silver sulfadiazine-induced acute renal failure. Ann Dermatol Venereol. 2005;132(11 Pt. 1):891–93. Doi: 10.1016/s0151-9638(05)79509-0.

40. Ormerod A., Thomas K., Craig F., et al. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the stop gap randomised controlled trial. BMJ. 2015;350:h2958. Doi: 10.1136/bmj.h2958.

41. Landis E., Taheri A., Jorizzo J. Gulliver’s sign: a recognizable transition from inflammatory to healing stages of pyoderma gangrenosum. J Dermatol Treat. 2015;26:171–72. Doi: 10.3109/09546634.2014.883061.

42. Brooklyn T.N. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55:505–9. Doi: 10.1136/gut.2005.074815.

43. Garieri P., Marcasciano M., Greto Ciriaco A., et al. Pyoderma gangrenosum and inflammatory bowel disease: a combined medical and surgical approach - case report and literature review. Eur Rev Med Pharmacol Sci. 2022;26(14):5191–99. Doi: 10.26355/eurrev_202207_29308.

44. Partridge A.C.R., Bai J.W., Rosen C.F., et al. Effectiveness of systemic treatments for pyoderma gangrenosum: a systematic review of observational studies and clinical trials. Br J Dermatol. 2018;179(2):290–95. Doi: 10.1111/bjd.16485.